JASON SPEES: Open Payments
NPI 1033762828 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$976 in 34 payments from 15 companies in 2025. Trend: 2023 $622 · 2024 $1,070 · 2025 $976
Food & beverage: $949Education: $27
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $245 |
| Lilly USA, LLC | 9 | $208 |
| GENZYME CORPORATION | 1 | $122 |
| Axsome Therapeutics, Inc. | 3 | $84 |
| Novo Nordisk Inc | 3 | $59 |
| Sumitomo Pharma America, Inc. | 3 | $53 |
| PFIZER INC. | 2 | $35 |
| ViiV Healthcare Company | 2 | $32 |
| Gilead Sciences, Inc. | 1 | $29 |
| ABBVIE INC. | 1 | $25 |
Products named: AIRSUPRA, ZEPBOUND, Auvelity, GEMTESA, JARDIANCE, MOUNJARO, Wegovy, NURTEC ODT.
Industry payments across TX — which companies pay providers there.
